Release – ISG to Announce First-Quarter Financial Results

Research News and Market Data on III

4/8/2026

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, said today it will release its first-quarter financial results on Thursday, May 7, 2026, at approximately 4:15 p.m., U.S. Eastern Time.

The firm will host a conference call with investors and industry analysts at 9 a.m., U.S. Eastern Time, the following day, Friday, May 8. Dial-in details are as follows:

  • The dial-in number for U.S. participants is +1 (800) 715-9871.
  • International participants should call +1 (646) 307-1963.
  • The security code to access the call is 6855650.

Participants are requested to dial in at least five minutes before the scheduled start time.

A recording of the conference call will be accessible on ISG’s investor relations page for approximately four weeks following the call.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Source: Information Services Group, Inc.

Xcel Brands (XELB) – Solid Foundation For Growth In 2026


Wednesday, April 08, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 Results. The company reported Q4 revenue of $1.2 million and an adj. EBITDA loss of $0.6 million, both of which were modestly lower than our estimates of $1.7 million and a loss of $0.5 million, respectively, as illustrated in Figure #1 Q4 Results. Notably, we view 2025 as a transformational year for the company, driven by several key partnerships that position it on a solid foundation for growth in 2026 and beyond. 

Strategic partnerships. The company’s influencer brands, with Jenny Martinez, Gemma Stafford, Cesar Millan, and Coco Rocha, are expected to launch throughout 2026. Notably, these partnerships have driven the company’s social media following from 5 million at the start of 2025 to approximately 46 million today. In our view, the company is well-positioned to reach its goal of 100 million social media followers in 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Greenwich LifeSciences, Inc. (GLSI) – New Claims Filed To Expand Patent Estate Covering GP2


Wednesday, April 08, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Data Added To Expand Patent Claims. Greenwich LifeSciences announced that it has filed new patent claims to expand the patent estate covering GP2, the proprietary compound in GLSI-100. The new claims add recently announced data from the Phase 3 FLAMINGO-01 trial that show the immune response and recurrence rate for non-HLA*02 patients. These claims could expand both the scope and the term of the patent estate beyond previous claims from HLA*02 patients.

Broadening Patent Protection Protects Against Competitors. Patent claims covering the immune response that results from GLSI-100 treatment could help lock out competitors trying to develop similar compounds. If a new compound were able to avoid patents covering GP2, it would be blocked by the new claims covering the immune response that follows.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

QuoteMedia Inc. (QMCI) – Revenue Momentum Picks Up


Wednesday, April 08, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Exceeds Q4 revenue expectations. QuoteMedia reported Q4 revenue of $5.35M (+14% y/y) and FY2025 revenue of $20.3M (+8% y/y), reflecting solid top-line momentum. Profitability declined in the full year 2025, with Adjusted EBITDA of $1.0M (vs. $1.8M prior year) and a net loss of $2.3 million, driven by investment and accounting treatment of development costs.

Key growth drivers. Revenue growth was led by Corporate Quotestream (enterprise), benefiting from larger contracts, higher ARPC, and cross-selling of data and SaaS solutions. Interactive Content revenue increased a strong 18.3%, better than our 8% growth estimate. Earnings were pressured by higher expensing of development costs (vs. capitalization), which impacted reported profitability.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GeoVax Labs (GOVX) – GeoVax Presents Data On New Single-Dose Mpox Vaccine


Wednesday, April 08, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Preclinical Study Compared Single-Dose MVA With Two-Dose Standard Vaccine. GeoVax presented preclinical data at the World Vaccine Congress Washington 2026 comparing its current pre-Phase-3 GEO-MVA vaccine for Mpox with its new MVA-X version. The new MVA-X includes a peptide sequence that elicits a strong T-cell response that requires only one dose to achieve protection instead of two.

Immune Checkpoint Modulation Improves The Response. The new MVA-X includes an immunomodulatory peptide designed to improve T-cell responses. The peptide modulates the PD-1 immune checkpoint pathway to block inhibitory signaling to magnify T-cell activation, improve the durability of the T-cell response, and enhance immune memory.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Direct Digital Holdings (DRCT) – Early Signs of Stabilization Emerge


Wednesday, April 08, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Post Q4 investor call. This report provides additional color on the recently reported fourth-quarter and full-year 2025 results and the outlook for 2026 and beyond. We are posting 2027 estimates, which anticipate mid-teen revenue growth and positive adj. EBITDA. 

New customer wins in energy and expanding vertical mix improve growth quality and reduce seasonality.
Buy-side momentum was driven by new customer additions, particularly in the energy vertical and by expansion into education. This diversification is helping stabilize revenue trends and reduce historical second-half weakness.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Xcel Brands, Inc. Announces Fourth Quarter Year-End 2025 Financial Results

Primary Logo

Research News and Market Data on XELB

April 7, 2026 at 4:55 PM EDT

PDF Version

  • Net loss on a GAAP basis was $2.8 million for the current quarter compared with a net loss of $7.1 million for the prior year quarter, each period inclusive of various non-cash charges, representing a $4.3 million improvement year-over-year.
  • Net loss on a non-GAAP basis was $1.6 million for the current and prior year quarters.
  • Current quarter Adjusted EBITDA was negative $0.61 million, compared with Adjusted EBITDA of negative $0.79 million for the prior year quarter, representing a 24% improvement.
  • Full year Adjusted EBITDA for 2025 was negative $2.3 million, compared with Adjusted EBITDA of negative $3.5 million for the prior year, representing a 35% improvement.

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company with significant expertise in livestream shopping and social commerce, today announced its financial results for the quarter and year ended December 31, 2025.

Robert W. D’Loren, Chairman and Chief Executive Officer of Xcel commented I am pleased with the progress we are making with our legacy brands and all of our new influencer led brands. These new influencer led brands will be launching throughout 2026.” He further commented, “the Company is on track to return to profitability, and we expect to achieve our goal of total brand portfolio reach of 100 million social media followers across our brands”.

Fourth Quarter 2025 Financial Results

Total revenue for the fourth quarter of 2025 was $1.2 million, flat from the prior year quarter.

Direct operating costs and expenses decreased approximately $0.6 million (-22%) from the prior year quarter to $2.2 million in the current quarter. This decrease reflects the various cost reduction actions previously taken by management to restructure and transform the Company’s business model. Currently, the Company has reduced its direct operating expenses to an expected run rate of less than $9 million per annum.

During the prior year quarter, the Company recognized a $3.9 million non-cash impairment charge attributable to the investment in the Isaac Mizrahi brand, whereby there was no similar charge in the current year quarter.

Net loss attributable to Xcel Brands stockholders for the quarter was approximately $2.8 million, or $(0.55) per share, compared with a net loss of $7.1 million, or $(3.00) per share, for the prior year quarter.

After adjusting certain cash and non-cash items, results on a non-GAAP basis were a net loss of approximately $1.6 million, or $(0.32) per share for the current quarter and a net loss of approximately $1.6 million, or $(0.69) per share, for the prior year quarter. Adjusted EBITDA was negative $0.61 million for the current quarter and negative $0.79 million in the prior year quarter, representing a year-over-year improvement of 24%.   

Full year 2025 Financial Results

Total revenue for the current year was $4.9 million, representing a decrease of approximately $3.3 million (42%) from the prior year. This decrease was primarily driven by a decline in net licensing revenue as a result of the June 30, 2024, divestiture of the Lori Goldstein brand, and to a lesser extent by the $0.35 million impact of the prior year sell-off of certain residual jewelry inventory and all remaining Longaberger inventory. However, management anticipates that the upcoming launches of new brands will drive revenue growth in 2026 and beyond.

Direct operating costs and expenses decreased approximately $4.2 million (-33%) from the prior year to $8.6 million in the current year. This decrease primarily reflects the various cost reductions previously taken by management to restructure and transform the Company’s business model, and to a lesser extent the impact of the divestiture of the Lori Goldstein brand in 2024.

During the current year, the Company recognized a $6.0 million non-cash loss to write the value of its investment in the Isaac Mizrahi brand down to zero, as well as a $1.9 million loss on early extinguishment of debt, related to the refinancing of its term loan debt.

Net loss attributable to Xcel Brands stockholders for the current year was approximately $17.5 million, or $(5.08) per share, compared with a net loss of $22.4 million, or $(9.84) per share, for the prior year. The prior year period results notably included a $11.8 million loss from equity method investments, predominantly attributable to the Isaac Mizrahi brand.

After adjusting for certain cash and non-cash items, results on a non-GAAP basis were a net loss of approximately $5.2 million, or $(1.52) per share for the current year and a net loss of approximately $5.1 million, or $(2.23) per share, for the prior year. Adjusted EBITDA was negative $2.3 million for the current year and negative $3.5 million in the prior year, representing a year-over-year improvement of 35%.

Balance Sheet

The Company’s balance sheet at December 31, 2025, reflected stockholders’ equity of approximately $15.8 million and unrestricted cash and cash equivalents of approximately $1.2 million. The Company’s balance sheet at December 31, 2025 also reflected $12.7 million of term loan debt, of which $3.3 million is payable in the next 12 months, whereby $1.0 million of restricted cash becomes unrestricted, and the majority of the interest expense is deferred until 2027.

Conference Call and Webcast

The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details at 5:00 p.m. Eastern Time on April 7, 2026. A webcast of the conference call will be available live on the Investor Relations section of Xcel’s website at www.xcelbrands.com. Interested parties unable to access the conference call via the webcast may dial 800-715-9871 or 646-307-1963 and use the conference ID 4508248. A replay of the webcast will be available on Xcel’s website.www.xcelbrands.com

About Xcel Brands

Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel owns the Halston, Judith Ripka, and C. Wonder brands, as well as the co-branded collaboration brands TowerHill by Christie Brinkley, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford and Off/Duty by Coco Rocha brand and also holds noncontrolling interests or long-term license agreement in MesaMia by Jenny Martinez. Xcel also owns and manages the Longaberger by Shannon Doherty brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customer’s shop. The company’s previously owned and current brands have generated in excess of $5 billion in retail sales via livestreaming in interactive television and digital channels alone, and has over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches in excess of 46 million social media followers with broadcast reach into 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding future events, our future financial performance, business strategy and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “ongoing,” “could,” “estimates,” “expects,” “intends,” “may,” “appears,” “suggests,” “future,” “likely,” “goal,” “plans,” “potential,” “projects,” “predicts,” “seeks,” “should,” “would,” “guidance,” “confident” or “will” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding our anticipated revenue, expenses, profitability, strategic plans and capital needs. These statements are based on information available to us on the date hereof and our current expectations, estimates and projections and are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors, including, without limitation, the risks discussed in the “Risk Factors” section and elsewhere in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its other filings with the SEC, which may cause our or our industry’s actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time, and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

For further information please contact:
Seth Burroughs
Xcel Brands
[email protected]

Non-GAAP net income and non-GAAP diluted EPS are non-GAAP unaudited terms. We define non-GAAP net income as net income (loss) attributable to Xcel Brands, Inc. stockholders, exclusive of amortization of trademarks, income (loss) from equity method investments, stock-based compensation and cost of licensee warrants, loss on early extinguishment of debt (if any), gains on sales of assets and investments (if any), asset impairment charges (if any), and income taxes (if any). Non-GAAP net income (loss) and non-GAAP diluted EPS measures do not include the tax effect of the aforementioned adjusting items, due to the nature of these items and the Company’s tax strategy.

Adjusted EBITDA is a non-GAAP unaudited measure, which we define as net income (loss) attributable to Xcel Brands, Inc. stockholders before interest and finance expenses (including loss on extinguishment of debt, if any), accretion of lease liability for exited leases, income taxes, other state and local franchise taxes, depreciation and amortization, income (loss) from equity method investments, asset impairment charges, stock-based compensation and cost of licensee warrants, gains on sales of assets and investments, and costs associated with restructuring of operations. Costs associated with restructuring of operations include operating losses generated by certain of our businesses that have been restructured or discontinued (i.e., wholesale apparel and fine jewelry), as well as non-cash charges associated with the restructuring of certain contractual arrangements.

Management uses non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA as measures of operating performance to assist in comparing performance from period to period on a consistent basis and to identify business trends relating to our results of operations. Management believes non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA are also useful because these measures adjust for certain costs and other events that management believes are not representative of our core business operating results, and thus these non-GAAP measures provide supplemental information to assist investors in evaluating our financial results.

Non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA should not be considered in isolation or as alternatives to net income, earnings per share, or any other measure of financial performance calculated and presented in accordance with GAAP. Given that non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA are financial measures not deemed to be in accordance with GAAP and are susceptible to varying calculations, our non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA may not be comparable to similarly titled measures of other companies, including companies in our industry, because other companies may calculate these measures in a different manner than we do. In evaluating non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA, you should be aware that in the future we may or may not incur expenses similar to some of the adjustments in this document. Our presentation of non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA does not imply that our future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating our performance, you should consider non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA alongside other financial performance measures, including our net income and other GAAP results, and not rely on any single financial measure.

View full release here.

Release – QuoteMedia Announces Financial Results for 2025 and Strong Growth Outlook

Research News and Market Data QMCI

PHOENIX, April 07, 2026 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of financial data solutions, today announced its fiscal year 2025 results, highlighted by an 8% increase in annual revenue to $20.3 million. The company concluded the year with significant momentum, reporting a 14% revenue jump in Q4 compared to the previous year.

QuoteMedia provides banks, brokerage firms, private equity firms, financial planners and sophisticated investors with a more economical, higher quality alternative source of stock market data and related research information. We compete with several larger legacy organizations and a modest community of other smaller companies.  QuoteMedia provides comprehensive market data services, including streaming data feeds, on-demand request-based data (XML/JSON), web content solutions (financial content for website integration) and applications such as Quotestream Professional desktop and mobile. 

Fiscal 2025 Financial Highlights (vs Fiscal 2024 unless otherwise noted):

  • Annual Revenue: $20,253,917, up 1,511,665 (8%) from 2024.
  • Q4 Revenue: $5,345,795, up $654,534 (14%) from Q4 2024.
  • Adjusted EBITDA(1): $1,018,485 compared to $1,778,478 in 2024, a decrease of $759,993.
  • Net Loss: $2,317,424 compared to a net loss of $1,327,037 in 2024, an increase of $990,387.

Management Commentary

“There are many positives to report in this year’s results,” said Robert J. Thompson, Chairman of the Board at QuoteMedia. “We delivered solid revenue growth, with an 8% increase year over year and a 14% rise in Q4 compared to the same period in 2024. We also finalized several key new contracts that are expected to begin contributing to revenue in 2026 and beyond. In addition, we are in late-stage discussions regarding further large-scale deployments, which we believe will support our continued growth.”

Despite these strong achievements, earnings and EBITDA declined significantly in 2025, primarily due to the accounting treatment of capitalized development costs:

  • A smaller proportion of development costs was capitalized compared to prior years, resulting in a higher level of immediate expense recognition.
  • As capitalized development costs are amortized over a three-year period, amortization expense remained elevated due to investments made in prior periods, temporarily reducing net income.
  • While these factors negatively impacted reported earnings and EBITDA, they had no effect on cash flow.

We expect gross margin, EBITDA, and overall profitability to continue improving in future quarters as our revenue grows, and the impact of higher amortization expenses related to prior period investments diminish.

Outlook

“We closed out 2025 on a strong note and anticipate that momentum will carry into 2026,” Thompson added. “Our sales pipeline remains solid, and we’re proud of our team’s ongoing success in winning and executing high-value contracts.”

Conference Call Details

QuoteMedia will host a conference call Wednesday, April 8, 2026, at 1:00 PM Eastern Time to discuss our 2025 financial results and provide a business update.

Conference Call Details:

Date: April 8, 2026

Time: 1:00 PM Eastern

Conference Link “Dial Me”: https://link.meetingpanel.com/?id=quotemedia-year-end-results

Dial-in numbers: 888-999-3182 Primary, 848-280-6330 Alternate

Conference ID: 3818457 PIN: 2420

An audio rebroadcast of the call will be available later at: www.quotemedia.com 

About QuoteMedia

QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies. The Company licenses interactive stock research tools such as streaming real-time quotes, market research, news, charting, option chains, filings, corporate financials, insider reports, market indices, portfolio management systems, and data feeds. QuoteMedia provides industry leading market data solutions and financial services for companies such as the Nasdaq Stock Exchange, TMX Group (TSX Stock Exchange), Canadian Securities Exchange (CSE), London Stock Exchange Group, FIS, U.S. Bank, Bank of Montreal (BMO), Broadridge Financial Systems, JPMorgan Chase, Scotiabank, CI Financial, Canaccord Genuity Corp., Hilltop Securities, Zacks Investment Research, General Electric, Boeing, Bombardier, Telus International, Business Wire, PR Newswire, The Goldman Sachs Group, Regal Securities, ChoiceTrade, Cetera Financial Group, Dynamic Trend, Inc., Credential Qtrade Securities, CNW Group, iA Private Wealth, Ally Invest, Inc., Suncor, Leede Jones Gable, Firstrade Securities, Charles Schwab, First Financial, Stock-Trak, Mergent, Cision and others. Quotestream®, QMod™ and Quotestream Connect™ are trademarks of QuoteMedia. For more information, please visit www.quotemedia.com.

Statements about QuoteMedia’s future expectations, including future revenue, earnings, and transactions, as well as all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. QuoteMedia intends that such forward-looking statements be subject to the safe harbors created thereby. These statements involve risks and uncertainties that are identified from time to time in the Company’s SEC reports and filings and are subject to change at any time. QuoteMedia’s actual results and other corporate developments could differ materially from that which has been anticipated in such statements.

Below are the specific forward-looking statements included in this press release:

  • We closed out 2025 on a strong note and anticipate that momentum will carry into 2026
  • We expect gross margin, EBITDA, and overall profitability to continue improving in future quarters as our revenue grows, and the impact of higher amortization expenses related to prior period investments diminishes

QuoteMedia Investor Relations

Dave Shworan
Email: [email protected] 
Call: (250) 954-3216 ext. 2101

Note 1 on Non-GAAP Financial Measures

We believe that Adjusted EBITDA, as a non-GAAP pro forma financial measure, provides meaningful information to investors in terms of enhancing their understanding of our operating performance and results, as it allows investors to more easily compare our financial performance on a consistent basis compared to the prior year periods. This non-GAAP financial measure also corresponds with the way we expect investment analysts to evaluate and compare our results. Any non-GAAP pro forma financial measures should be considered only as supplements to, and not as substitutes for or in isolation from, or superior to, our other measures of financial information prepared in accordance with GAAP, such as net income attributable to QuoteMedia, Inc.

We define and calculate Adjusted EBITDA as net income attributable to QuoteMedia, Inc., plus: 1) depreciation and amortization, 2) stock compensation expense, 3) interest expense, 4) foreign exchange loss (or minus a foreign exchange gain), and 5) income tax expense. We disclose Adjusted EBITDA because we believe it is a useful metric by which to compare the performance of our business from period to period. We understand that measures similar to Adjusted EBITDA are broadly used by analysts, rating agencies, investors and financial institutions in assessing our performance. Accordingly, we believe that the presentation of Adjusted EBITDA provides useful information to investors. The table below provides a reconciliation of Adjusted EBITDA to net income attributable to QuoteMedia, Inc., the most directly comparable GAAP financial measure.

News Provided by GlobeNewswire via QuoteMedia

Release – Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

Research News and Market Data on GLSI

 Download as PDF

April 07, 2026 6:00am EDT

STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data.

  • Statistically significant immune response and recurrence rate data is the basis for new claims recently filed that GLSI-100 clinically benefits non-HLA-A*02 patients, which the Company believes increases the market for GLSI-100 by an additional 100% to 88,000 new patients per year in the US and Europe.
  • The claims also show a favorable comparison to the blinded HLA-A*02 arms of FLAMINGO-01, without any unblinding.
  • The invention is solely owned by the Company. If the patent claims are granted, following successful patent prosecution, the patent could provide patent protection through 2045.

The Company plans to expand its immune response analysis of GP2 specific T cells by sequencing the DNA of a patient’s T cells at baseline and after treatment with GP2. The T cell sequences can be compared to the immune response changes over time.

CEO Snehal Patel commented, “We believe that these patent claims, based on statistically significant data, support the enrollment of patients independent of HLA type. In the US, we have already started to enroll both HLA-A*02 and non-HLA-A*02 patients in the same randomized arms in FLAMINGO-01, based on the FDA’s recent review of such protocol changes. The Company will have the option to pursue approval for both HLA-A*02 and non-HLA-A*02 patients using the increased statistical power of a combined analysis of the two patient groups together with the potential to double the market for GP2 to up to $10 billion in revenue per year.”

About FLAMINGO-01 Open Label Phase III Data

More than 1,000 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.

  • In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 80% reduction in recurrence rate.
  • This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
  • The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.

Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About GLSI-100 Phase IIb Study

In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:

  • 80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.
  • The PIS elicited a potent immune response as measured by local skin tests and immunological assays.

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the “Contacts and Locations” section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]

Primary Logo

Source: Greenwich LifeSciences, Inc.

Released April 7, 2026

Capital Goods Orders Beat in February, But Middle East Conflict Puts March — and Small-Cap Shippers — on Watch

U.S. business investment showed unexpected resilience in February, but the window may be closing fast.

New orders for core capital goods — the government’s closely watched proxy for business spending — rose 0.6% in February, topping economist forecasts of a 0.4% gain and reversing a revised 0.4% decline in January. Shipments of those same goods climbed 0.9%, adding further evidence that equipment spending was gaining traction heading into the first quarter. The Commerce Department’s Census Bureau released the data Tuesday.

The numbers paint a picture of solid momentum — but one that was captured before the full weight of the U.S.-Israel war with Iran began reshaping the investment landscape. Oil prices have climbed, supply chains are tightening, and businesses that were leaning forward in February are now likely pulling back to reassess.

Orders Show Broad Strength — With One Glaring Exception

February’s gains were driven by solid increases across primary metals, fabricated metal products, and machinery, which jumped 1.5%. Motor vehicles and parts surged 3.1%. The broad picture was encouraging for domestic manufacturers.

The one glaring exception: commercial aircraft. Boeing reported just 21 civilian aircraft orders in February, down sharply from 107 in January — a 28.6% collapse in commercial aircraft orders that dragged overall durable goods orders down 1.4% for the month. Defense aircraft orders also fell 3.8%.

Durable goods as a category declined for the second consecutive month, though stripping out the volatile transportation segment, orders actually rose a healthy 0.8%.

Supply Chains Are Already Feeling the Pressure

Perhaps the most forward-looking signal in Tuesday’s data wasn’t in the orders figures at all — it was in what’s happening to delivery times. An Institute for Supply Management manufacturing survey released last week showed supplier delivery times stretching to a four-year high in March, a direct consequence of the geopolitical disruption rippling through global logistics networks.

That’s a number that matters deeply to companies like EuroDry (NASDAQ: EDRY) and Euroseas (NASDAQ: ESEA), both dry bulk operators that move iron ore, coal, grains, and other bulk commodities across ocean routes. Longer delivery windows mean more time at sea per cargo cycle, which can translate to tighter effective vessel supply and, in some market conditions, upward pressure on charter rates. EuroDry posted a strong Q4 2025 earnings beat in February and has expanded its forward charter book heading into 2026 — but the Iran conflict introduces a new variable around route disruption and fuel costs that management will need to navigate carefully.

For FreightCar America (NASDAQ: RAIL), the February machinery and motor vehicle data is directionally constructive. The company entered 2026 projecting growth, backed by a strong backlog and expanding margins. But if industrial order momentum stalls in March and April as businesses hit pause on capex decisions — as many economists now expect — railcar demand tied to manufacturing output could soften in the back half of the year.

The AI Wildcard

One consistent bright spot cutting through the uncertainty: artificial intelligence. Data center construction and the infrastructure buildout supporting AI workloads continue to drive demand for raw materials, electricity, and the bulk commodities that companies like EuroDry and Euroseas specialize in moving. That structural tailwind isn’t going away regardless of where energy prices settle.

February’s capital goods data was a genuine beat. The question now is whether it’s the last clean read for a while — or a foundation that holds even as the macro backdrop gets more complicated.

Newsmax (NMAX) – Structural Growth Story Intact; Tweaking Price Target


Tuesday, April 07, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Q4 execution with continued top-line momentum. Newsmax delivered Q4 revenue growth of 9.6% year-over-year, driven by affiliate fee expansion and resilient advertising demand, outperforming expectations in a non-election year environment. The company continues to scale across cable, streaming (FAST), subscription, and digital platforms, expanding distribution to 100+ countries and reinforcing its position as the #4 cable news network.

Affiliate fee upside remains key long-term catalyst. Ongoing contract renewals and repricing opportunities provide meaningful upside potential, with current rates still significantly below industry peers. Based on recent contracts and a favorable 2026 outlook, we have revised our 2026 affiliate fee revenue estimate upward from $43.4 million to $49.8 million. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Century Lithium Corp. (CYDVF) – Moving to the Next Phase of Development


Tuesday, April 07, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Updated feasibility study. Century recently filed its updated 2026 NI 43-101 feasibility study for its 100%-owned Angel Island Lithium Project in Nevada. The updated study reflects engineering optimization and improvements that materially strengthen the project’s economic profile and highlight Angel Island as one of the most significant and economically robust sedimentary lithium developments in the United States.

Next steps. With the completion and filing of the 2026 Feasibility Study and the recent C$7 million financing, the company is well positioned to advance the Angel Island project to its next development stages. Planned activities include submitting a Plan of Operations to the Bureau of Land Management to initiate the National Environmental Policy Act (NEPA) review process, advancing Nevada state permitting, progressing detailed engineering, and continuing engagement with strategic and downstream partners. Century also intends to further evaluate the rate of earth element recovery at Angel Island and continue discussions with potential offtake and project finance partners.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Will This Be TACO All Over?

Markets have seen this movie before. President Trump draws a line, the rhetoric peaks, and then — nothing. Or at least, not the nothing anyone expected. But with an 8 p.m. Tuesday deadline for Iran to reopen the Strait of Hormuz or face the destruction of every bridge and power plant in the country, investors are asking the same uncomfortable question: is this another TACO moment — Trump Always Chickens Out — or is this time fundamentally different?

For those unfamiliar, TACO became market shorthand during the tariff wars, describing the pattern where Trump’s most extreme threats would eventually soften into a negotiated pause. Buy the dip, ignore the headline, collect the bounce. It worked repeatedly. But the Iran conflict is not a tariff dispute, and the Strait of Hormuz is not a trade negotiation table.

The stakes are materially different this time. The closure of the Strait has triggered sharp rises in global energy prices, with hikes as high as 20% to 30% at the pumps across the United States and Europe. U.S. benchmark West Texas Intermediate climbed to $115.48 per barrel on Monday, with Brent crude close behind at nearly $112. That is not rhetorical damage — that is real economic pain being absorbed by businesses and consumers right now.

Trump has issued similar ultimatums on several occasions in recent weeks, delaying the deadline each time. That track record feeds the TACO narrative. But there is a critical distinction: U.S. forces have already conducted new strikes on military targets on Iran’s Kharg Island — the country’s primary oil export hub — signaling this administration is not simply posturing.

For small and microcap investors, the practical implications are already being felt across the supply chain. Supplier delivery times hit a four-year high in March according to the ISM manufacturing survey. Companies like EuroDry (NASDAQ: EDRY) and Euroseas (NASDAQ: ESEA), which move bulk commodities through ocean routes increasingly disrupted by the conflict, are navigating a market where route uncertainty and elevated fuel costs are compressing margins and complicating charter rate forecasting. Both companies entered 2026 with momentum — but a prolonged Hormuz closure rewrites the calculus entirely.

On the rail side, FreightCar America (NASDAQ: RAIL) built its 2026 growth case on a stable industrial demand environment. If energy price spikes force manufacturers to pause capital equipment orders — which February data already hints at for March and beyond — railcar demand tied to that manufacturing activity faces real downside risk in the back half of the year.

Iran has responded with defiance, calling Trump’s threats baseless and warning that any retaliation will be far more forceful and on a much wider scale. Talks are ongoing through intermediaries including Pakistan, Egypt, and Turkey, and a negotiated off-ramp is still possible.

The TACO trade assumes that off-ramp always materializes. It may. But the window for dismissing this as noise is closed. Whether Trump blinks or follows through tonight, the Strait of Hormuz crisis is already doing damage — and for small-cap companies tied to global shipping and industrial demand, every hour of uncertainty has a price.